Pharmacological management of tics in patients with TS.
This article reviews the evidence published in the English language literature concerning the pharmacological treatment of tics in patients with Tourette Syndrome. The focus is on the efficacy and safety of the current treatments. A clinical approach to pharmacological management of Tourette Syndrome patients is outlined.
Sandor
Paul
P
Department of Psychiatry, Toronto Western Hospital, Edith-Cavell Wing, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8. paul.sandor@uhn.on.ca
D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D003000:Clonidine / Q000627:therapeutic use; D018492:Dopamine Antagonists / Q000627:therapeutic use*; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D017410:Practice Guidelines as Topic; D013565:Sympatholytics / Q000627:therapeutic use*; D013747:Tetrabenazine / Q000627:therapeutic use; D020323:Tics / Q000188:drug therapy*; D005879:Tourette Syndrome / Q000188:drug therapy*
D018726:Anti-Dyskinesia Agents; D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D013565:Sympatholytics; D006220:Haloperidol; D003000:Clonidine; D013747:Tetrabenazine